Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 259
8
Diseases
7
Unique genes
0.306
Avg. similarity score
Gastrin-producing neuroendocrine tumor
Most-connected disease (5 links)
Disease
Searched: Multiple endocrine neoplasia type 4
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Multiple endocrine neoplasia type 4
Gastrin-producing neuroendocrine tumor
Multiple endocrine neoplasia type 1
Pancreatic glucagonoma
Pancreatic somatostatinoma
Pituitary gigantism
Thyroid-stimulating hormone-secreting pituitary adenoma
Erythrocytosis, familial, 4
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Gastrin-producing neuroendocrine tumor | 5 | 5 | 1 |
| Multiple endocrine neoplasia type 1 | 5 | 5 | 5 |
| Pancreatic glucagonoma | 5 | 5 | 1 |
| Pancreatic somatostatinoma | 5 | 5 | 2 |
| Pituitary gigantism | 5 | 5 | 2 |
| Thyroid-stimulating hormone-secreting pituitary adenoma | 5 | 5 | 1 |
| Erythrocytosis, familial, 4 | 1 | 1 | 1 |
| Multiple endocrine neoplasia type 4 | 1 | 1 | 1 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| MEN1 | 6 / 8 | Gastrin-producing neuroendocrine tumor, Multiple endocrine neoplasia type 1, Pancreatic glucagonoma, Pancreatic somatostatinoma and 2 more |
| CDKN1B | 2 / 8 | Multiple endocrine neoplasia type 1, Multiple endocrine neoplasia type 4 |
| EPAS1 | 2 / 8 | Erythrocytosis, familial, 4, Pancreatic somatostatinoma |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Cushing syndrome | KEGG | 6 / 155 | 66.4× | 2.91e-11 | 3.98e-9 ✓ sig. |
| Cyclin D associated events in G1 | Reactome | 4 / 44 | 156× | 5.44e-9 | 4.28e-7 ✓ sig. |
| Senescence-Associated Secretory Phenotype (SASP) | Reactome | 4 / 111 | 61.8× | 2.37e-7 | 1.19e-5 ✓ sig. |
| Cell cycle | KEGG | 4 / 158 | 43.4× | 9.79e-7 | 4.09e-5 ✓ sig. |
| Transcriptional misregulation in cancer | KEGG | 4 / 198 | 34.7× | 2.41e-6 | 8.85e-5 ✓ sig. |
| p53-Dependent G1 DNA Damage Response | Reactome | 2 / 7 | 490× | 6.11e-6 | 1.94e-4 ✓ sig. |
| Small cell lung cancer | KEGG | 3 / 93 | 55.3× | 1.54e-5 | 4.19e-4 ✓ sig. |
| AKT phosphorylates targets in the cytosol | Reactome | 2 / 11 | 312× | 1.60e-5 | 4.32e-4 ✓ sig. |
| Endocrine resistance | KEGG | 3 / 99 | 52.0× | 1.86e-5 | 4.90e-4 ✓ sig. |
| HIF-1 signaling pathway | KEGG | 3 / 110 | 46.8× | 2.55e-5 | 6.37e-4 ✓ sig. |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | Reactome | 2 / 14 | 245× | 2.64e-5 | 6.54e-4 ✓ sig. |
| FoxO signaling pathway | KEGG | 3 / 133 | 38.7× | 4.50e-5 | 1.01e-3 ✓ sig. |
| Gastric cancer | KEGG | 3 / 150 | 34.3× | 6.44e-5 | 1.34e-3 ✓ sig. |
| Constitutive Signaling by AKT1 E17K in Cancer | Reactome | 2 / 25 | 137× | 8.68e-5 | 1.70e-3 ✓ sig. |
| Cyclin E associated events during G1/S transition | Reactome | 2 / 28 | 123× | 1.09e-4 | 2.04e-3 ✓ sig. |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| regulation of G1/S transition of mitotic cell cycle | GO:2000045 | 4 / 57 | 187× | 2.70e-9 | 5.55e-7 ✓ sig. |
| negative regulation of cardiac muscle tissue regeneration | GO:1905179 | 2 / 2 | 2,670× | 1.20e-7 | 1.48e-5 ✓ sig. |
| negative regulation of cell population proliferation | GO:0008285 | 5 / 444 | 30.1× | 1.50e-7 | 1.79e-5 ✓ sig. |
| negative regulation of cyclin-dependent protein kinase activity | GO:1904030 | 2 / 3 | 1,780× | 3.61e-7 | 3.69e-5 ✓ sig. |
| cellular response to cell-matrix adhesion | GO:0071460 | 2 / 4 | 1,335× | 7.21e-7 | 6.58e-5 ✓ sig. |
| cellular senescence | GO:0090398 | 3 / 57 | 141× | 9.34e-7 | 8.13e-5 ✓ sig. |
| negative regulation of cyclin-dependent protein serine/threonine kinase activity | GO:0045736 | 2 / 9 | 593× | 4.32e-6 | 2.82e-4 ✓ sig. |
| regulation of cell cycle G1/S phase transition | GO:1902806 | 2 / 11 | 485× | 6.60e-6 | 3.94e-4 ✓ sig. |
| negative regulation of cell growth | GO:0030308 | 3 / 115 | 69.6× | 7.81e-6 | 4.51e-4 ✓ sig. |
| negative regulation of growth | GO:0045926 | 2 / 18 | 297× | 1.84e-5 | 8.67e-4 ✓ sig. |
| positive regulation of DNA replication | GO:0045740 | 2 / 29 | 184× | 4.86e-5 | 1.81e-3 ✓ sig. |
| positive regulation of transforming growth factor beta receptor signaling pathway | GO:0030511 | 2 / 34 | 157× | 6.71e-5 | 2.29e-3 ✓ sig. |
| negative regulation of vascular associated smooth muscle cell proliferation | GO:1904706 | 2 / 43 | 124× | 1.08e-4 | 3.27e-3 ✓ sig. |
| DNA damage response, signal transduction by p53 class mediator | GO:0030330 | 2 / 48 | 111× | 1.35e-4 | 3.82e-3 ✓ sig. |
| response to UV | GO:0009411 | 2 / 54 | 98.9× | 1.71e-4 | 4.53e-3 ✓ sig. |